ORCID Profile
0000-0001-8434-4430
Current Organisation
NHS Highland
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Springer Science and Business Media LLC
Date: 18-09-2019
DOI: 10.1186/S13104-019-4625-1
Abstract: Fetal macrosomia is a major risk factor for shoulder dystocia, which can lead to birth asphyxia, maternal and neonatal traumatic injuries, and perinatal death. If macrosomia is diagnosed in the antenatal period, labour can be induced to decrease shoulder dystocia. But current clinical methods to diagnose fetal macrosomia antenatally perform with poor accuracy. Therefore, improved methods to accurately diagnose fetal macrosomia are required. Blood biomarkers that predict fetal macrosomia could be one such novel diagnostic strategy. We undertook a nested case–control study from a prospective collection of 1000 blood s les collected at 36 weeks’ gestation. We analysed plasma s les from 52 women who subsequently delivered a macrosomic ( 95th centile for gestational age) infant and 106 controls. Circulating concentrations of the proteins COBLL1, CSH1, HSD3B1, EGFL6, XAGE3, S100P, PAPPA-1, ERBB2 were assessed for their ability to predict macrosomic infants. We did not identify any significant changes in the plasma concentrations of COBLL1, CSH1, HSD3B1, EGFL6, XAGE3, S100P, PAPPA-1, ERBB2 from women who subsequently delivered macrosomic neonates relative to control s les. Although we have not identified any potential biomarkers of fetal macrosomia, we have ruled out these particular eight protein candidates.
Publisher: Elsevier BV
Date: 02-2020
Publisher: Springer Science and Business Media LLC
Date: 31-08-2018
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 17-08-2120
Abstract: We investigated the biomarker potential of growth differentiation factor 15 (GDF‐15), a stress response protein highly expressed in placenta, to predict preecl sia. In 2 prospective cohorts (cohort 1: 960 controls, 39 women who developed preecl sia cohort 2: 950 controls, 41 developed preecl sia), plasma concentrations of GDF‐15 at 36 weeks' gestation were significantly increased among those who developed preecl sia ( P .001), area under the receiver operating characteristic curves (AUC) of 0.66 and 0.71, respectively. In cohort 2 a ratio of sFlt‐1/PlGF (a clinical biomarker for preecl sia) had a sensitivity of 61.0% at 83.2% specificity to predict those who will develop preecl sia (AUC of 0.79). A ratio of GDF‐15×sFlt‐1/PlGF yielded a sensitivity of 68.3% at 83.2% specificity (AUC of 0.82). GDF‐15 was consistently elevated across a number of international cohorts: levels were higher in placenta and blood from women delivering weeks' gestation due to preterm preecl sia in Melbourne, Australia and in the blood at 26 to 32 weeks' gestation among 57 women attending the Manchester Antenatal Vascular Service (MAViS, UK) who developed preecl sia ( P =0.0002), compared with 176 controls. In the Preecl sia Obstetric adVerse Events biobank (PROVE, South Africa), plasma GDF‐15 was significantly increased in women with preecl sia with severe features ( P =0.02 n=14) compared to controls (n=14). We conclude circulating GDF‐15 is elevated among women more likely to develop preecl sia or diagnosed with the condition. It may have value as a clinical biomarker, including the potential to improve the sensitivity of sFlt‐1/PlGF ratio.
Location: United Kingdom of Great Britain and Northern Ireland
No related grants have been discovered for Kirsten Dane.